RxDoctor Payments Data

Tonya Yoney, DO

Family Medicine · Yucaipa, CANPI 1013186923

Payments from drug & device makers

$2,465in general payments, 2019–2025

Across 89 payments — averaging $27.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$577
  • Boehringer Ingelheim$239
  • Evolution Surgical, Inc$226
  • Abbott$223
  • Corcept Therapeutics$193
  • Bayer$170
  • plus $837 from 13 others

What the payments were for

  • Food & beverage$2,465100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,465 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$38,462
Medicare patients
129
Services billed
530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban64$61,355
OzempicSemaglutide52$57,697
MounjaroTirzepatide25$23,991
JanuviaSitagliptin Phosphate17$22,063
MyrbetriqMirabegron34$18,767
LinzessLinaclotide17$14,395
XareltoRivaroxaban11$14,251
JardianceEmpagliflozin12$12,673
PremarinEstrogens, Conjugated24$9,379
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$6,665
Levothyroxine Sodium300$5,508
Albuterol Sulfate HfaAlbuterol Sulfate137$5,238
Omega-3 Acid Ethyl Esters42$4,850
Breo ElliptaFluticasone/Vilanterol12$4,391
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$4,332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$49$70,73488 claims
Novo NordiskOzempic$134$57,69752 claims
Lilly USA, LLCMounjaro$129$23,99125 claims
MerckJanuvia$117$22,06317 claims
Astellas Pharma US IncMyrbetriq$44$18,76734 claims
AbbVieLinzess, Synthroid, Armour Thyroid$139$18,75583 claims
Johnson & JohnsonXarelto$40$14,25111 claims
Boehringer IngelheimJardiance$239$12,67312 claims
GSKAnoro Ellipta, Breo Ellipta$40$11,05624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Yucaipa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →